Former Chair, Vividion Therapeutics
Rich Heyman, PhD, most recently served as Chairman of Vividion Therapeutics, which was purchased in August 2021 by Bayer Pharma. He is the co-founder and Chairman of both ORIC Pharmaceuticals, which is developing drugs to overcome resistance in cancer and Metacrine Inc., developing therapeutics for liver and gastrointestinal diseases. Previously, Rich was the co-founder and CEO of Aragon and Seragon Pharmaceuticals, which focused on therapeutics targeting hormone dependent cancers. J&J purchased Aragon in 2013 and Genentech purchased Seragon in 2014. He has been involved in the discovery and development of multiple therapeutic agents approved by the FDA, including the prostate cancer drug, Erleada. Dr. Heyman is a Venture Partner for Arch Ventures and serves as Chairman of Amunix Pharma and PMV Pharma, as well as serving on the BOD of Gritstone Bio, Enliven Therapeutics and Yumanity Therapeutics. In addition to his corporate experience, Rich is Vice Chair of the Board of Trustees at the Salk Institute, on the Board Foundation for the AACR, the Executive Committee at the UCSD Moores Cancer Center and a founding member of Life Science Cares, San Diego. He has won numerous awards including Ernst and Young San Diego Regional Entrepreneur of the Year and the Endocrine Society Outstanding Innovation Award. Earlier in his career he trained as an NIH postdoctoral fellow and staff scientist at the Salk Institute. Rich is the author or inventor on more than 125 publications and patents.